Conflict of interest: C. Celis-Preciado has received an education scholarship from the Université de Sherbrooke, within the current work; outside the current work, he has received speaker honoraria from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron, and received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron. S. Lemaire-Paquette reports no potential conflicts of interest. P. Lachapelle reports speaker honoraria from AstraZeneca, Sanofi-Regeneron, GlaxoSmithKline, Boehringer Ingelheim and Novartis, and received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron, outside the submitted work. S. Couillard reports within the submitted work, he has received non-restricted research grants from Sanofi-Genyme-Regeneron, bioMérieux, Circassia Niox Group and the Québec Air-Intersectorialité-Respiratoire Network; he is the holder of the Association Pulmonaire du Québec's Research Chair in Respiratory medicine and is a clinical research scholar of the Fonds de recherche du Québec; outside the submitted work, he reports non-restricted research grants from NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Fondation Québécoise en Santé Respiratoire and AstraZeneca, speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron and Valeo Pharma, consultancy fees from FirstThought, AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Access Biotechnology and Access Industries, and sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron; he is an advisory board member and holds stock options for Biometry Inc., a company developing a FeNO device (myBiometry), he advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners, and is a member of the asthma steering committee of the Canadian Thoracic Society.